Supergene, Llc

This Phase 3 trial tests a drug called Fortelyzin® (non-immunogenic staphylokinase) in 990 adults with acute ischemic stroke who can be treated between 4.5 and 24 hours after symptoms begin. Participants receive a single injection of the drug or a placebo. The goal is to see if t…

This study tests a single injection of a clot-dissolving drug (staphylokinase) in 486 adults with intermediate high-risk pulmonary embolism—a serious blood clot in the lungs. The goal is to see if it prevents death, heart collapse, or another clot compared to a placebo. Participa…

This study tests a drug called Fortelyzin, which is injected directly into blood clots to dissolve them, in people with acute limb ischemia (sudden loss of blood flow to a limb). The goal is to see if it can prevent amputation as well as or better than standard surgery. About 170…

This registry is studying a drug called non-immunogenic staphylokinase (Fortelyzin®) given as a single injection to dissolve blood clots in the lungs. It will include up to 20,000 adults with massive pulmonary embolism who are already receiving the drug in routine care. The goal …